Paion AG is a biopharmaceutical company focused on developing and commercializing innovative drugs for anesthesia and sedation. Its lead product, Remimazolam, is a short-acting benzodiazepine that has received regulatory approval in various markets, including Europe and Japan, positioning the company to capture significant market share in the anesthetic drug segment.
Business Overview
Paion AG generates revenue primarily through the sale of Remimazolam, which is marketed for procedural sedation and general anesthesia. The company benefits from high gross margins of 94.1%, indicating strong pricing power and low production costs relative to sales.
Regulatory approvals for Remimazolam in new markets
Partnership agreements for distribution and marketing
Clinical trial results for new indications of Remimazolam
Market adoption rates in key geographies such as Europe and Japan
Risk Factors
Regulatory changes affecting drug approval processes
Technological disruption in anesthesia practices
Emergence of alternative anesthetic agents
Pricing pressure from generic competitors
High debt-to-equity ratio of 3.08, indicating potential liquidity issues
Negative net income margin could impact future funding opportunities
Macro Sensitivity
low - The demand for anesthesia drugs like Remimazolam is relatively inelastic, as they are essential for medical procedures regardless of economic conditions.
Minimal impact as the company does not rely heavily on debt financing, but higher rates could affect overall healthcare spending indirectly.
minimal - The company has low debt levels, which reduces sensitivity to credit conditions.
Profile
growth - Investors seeking exposure to innovative biopharmaceuticals with high growth potential.
high - The stock may exhibit high volatility due to its reliance on regulatory approvals and clinical trial outcomes.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
